Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Trial ID or NCT#
NCT00233454
Status
NOT RECRUITING
Purpose
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
Official Title
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Andrea Linder
6507254047
View on ClinicalTrials.gov
